Back to School: How biopharma can reboot drug development. Access exclusive analysis here

AdPEDF: Phase I interim data

Interim data from an open-label, dose-escalation, U.S. Phase I

Read the full 94 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE